Daily Bulletin

New data independently confirms and extends laboratory findings and expands safety profile of ATH434-PR Newswire APAC

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Cision

MELBOURNE, Australia and SAN FRANCISCO, Aug. 4, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for presentation at the 2020 International Congress of...

Read more: New data independently confirms and extends laboratory findings and expands safety profile of...

More Articles ...

  1. Tile™ and Skullcandy Create Most Advanced True Wireless Finding Experience-PR Newswire APAC
  2. Trade360 Announces New Trading Platform-PR Newswire APAC
  3. Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report-PR Newswire APAC

Business News

The Importance of a Branding Agency for Your Business

Brand building is not only a logo or a catchy tagline. It's about how your business is seen, links with clients, and stands out in crowded markets. Whether you are a start-up or an established busin...

Daily Bulletin - avatar Daily Bulletin

Website Development Costs

When it comes to building a website, the scope and complexity of the project play a major role in determining the cost. Whether you need a simple landing page or a complex e-commerce platform, the...

Daily Bulletin - avatar Daily Bulletin

Major Steps to Take When Starting a Medical Billing Business

The healthcare industry continues to expand every day. If you have been thinking about starting a medical billing business, you are on the right track. This is a good business idea that can help you l...

Daily Bulletin - avatar Daily Bulletin